Kathleen Gordon, DO
Internal Medicine · Johnston, RINPI 1861417354
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,978 of the $15,714 with a category attached, or 63.5%. 52 manufacturers reported payments, led by Eli Lilly at 29.5% of the total. Reporting peaked in 2019 at $5,084 and has fallen 63.4% since, to $1,861 in 2025. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 505 payments — averaging $31.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$5K
- Pfizer$2K
- AbbVie$2K
- AstraZeneca$968
- GSK$894
- Vanda Pharmaceuticals Inc.$757
- plus $5K from 46 others
Across 523 payments — averaging $2047.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$397K
- AbbVie$344K
- Sanofi US Services Inc.$102K
- Pfizer$77K
- Eli Lilly$52K
- Sun Pharmaceutical Industries Inc.$52K
- plus $48K from 4 others
What the payments were for
- Consulting fees$3,75024%
- Travel & lodging$1,92512%
- Food & beverage$9,97863%
- Education$610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reblozyl$122
How this compares
$15,714 in reported general payments places this provider in the 95th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $52,721 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $33,600 |
| JanuviaSitagliptin Phosphate | 43 | $26,339 |
| Metformin Er OsmoticMetformin Hcl | 13 | $7,140 |
| FarxigaDapagliflozin Propanediol | 24 | $6,788 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $6,782 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,275 |
| Omeprazole | 412 | $5,505 |
| VascepaIcosapent Ethyl | 13 | $5,022 |
| Atorvastatin Calcium | 465 | $4,953 |
| Losartan Potassium | 374 | $4,897 |
| Levothyroxine Sodium | 405 | $4,766 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $3,486 |
| SynthroidLevothyroxine Sodium | 58 | $3,478 |
| Amlodipine Besylate | 332 | $3,138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,270 | $52,721133 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $894 | $39,87566 claims |
| MerckJanuvia | $32 | $26,33943 claims |
| AstraZenecaFarxiga | $968 | $6,78824 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $4,766405 claims |
| AbbVieSynthroid | $1,673 | $3,47858 claims |
| Lilly USA, LLCHumalog Mix 75-25 | $113 | $1,22413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Johnston
- Stephanie DrainvilleJohnston$11K
- Kiley ToderJohnston$7K
- P Wilfredo CanchisJohnston$5K
- William BeliveauJohnson$951K
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Frank D'alessandroLincoln$93K
- Gregory AllenCranston$38K
- Richard RuggieriProvidence$30K
- Gerry OvideProvidence$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.